文献速递儿科与产科急症呼吸衰竭与机械通气

尼塞韦单抗与RSVpreF疫苗对新生儿呼吸道合胞病毒相关住院的比较

Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.
PubMed 文献 · JAMA · 2026-01-01
一句话结论在法国2024年RSV流行季,婴儿被动免疫用尼塞韦单抗较母亲接种RSVpreF疫苗与更低的RSV相关住院和重症风险相关。

这项基于法国国家健康数据系统的队列研究纳入2024年9月1日至12月31日在法国本土出生、按分娩病房出院日期、性别、胎龄和地区1:1匹配的42560名婴儿(每组21280名),比较母亲妊娠32至36周接种RSVpreF疫苗与婴儿出院前接受尼塞韦单抗被动免疫对RSV相关下呼吸道感染住院的关联。中位随访84天,尼塞韦单抗组发生212例(44.1%)RSV相关住院,RSVpreF疫苗组269例(55.9%),组间差异-11.8%(95%CI -18.1%至-5.5%);校正HR 0.74(95%CI 0.61-0.88)。尼塞韦单抗还与更低的PICU入住(校正HR 0.58,95%CI 0.42-0.80)、需要呼吸机支持(校正HR 0.57,95%CI 0.40-0.81)和需要氧疗(校正HR 0.56,95%CI 0.38-0.81)风险相关。作者认为这些结果反映法国本土首次使用这两种免疫策略的RSV流行季,其使用应在未来研究中重新评估。

要点

  • 尼塞韦单抗组RSV相关下呼吸道感染住院212例(44.1%) vs RSVpreF疫苗组269例(55.9%),组间差异-11.8%(95%CI -18.1%至-5.5%)。
  • 与母亲接种RSVpreF疫苗相比,婴儿尼塞韦单抗被动免疫与RSV相关住院风险更低相关(校正HR 0.74,95%CI 0.61-0.88)。
  • 尼塞韦单抗还与更低的PICU入住风险相关(校正HR 0.58,95%CI 0.42-0.80)。
  • 尼塞韦单抗与更低的需呼吸机支持风险相关(校正HR 0.57,95%CI 0.40-0.81),需氧疗风险亦更低(校正HR 0.56,95%CI 0.38-0.81)。
  • 作者认为这些结果反映法国本土首次使用这两种免疫策略的RSV流行季,其使用应在未来研究中重新评估。

适用人群与场景

  • 2024年9月1日至12月31日在法国本土出生的婴儿,母亲在妊娠32至36周接种RSVpreF疫苗或婴儿出院前接受尼塞韦单抗被动免疫。
  • 共纳入42560名婴儿(每组21280名),平均年龄3.7天(SD 1.4),51.7%为男性,中位随访84天(IQR 70-99天)。

处置流程与药物剂量

  • 母亲妊娠32至36周接种RSVpreF疫苗。
  • 婴儿出院前接受尼塞韦单抗被动免疫。

研究设计与关键结果

  • 研究类型:基于法国国家健康数据系统的人群队列研究,婴儿按分娩病房出院日期、性别、胎龄和地区1:1匹配。
  • 主要终点:RSV相关下呼吸道感染住院共481例,尼塞韦单抗组212例(44.1%) vs RSVpreF疫苗组269例(55.9%),组间差异-11.8%(95%CI -18.1%至-5.5%);与RSVpreF疫苗相比,尼塞韦单抗校正HR 0.74(95%CI 0.61-0.88)。
  • 关键次要终点:PICU入住校正HR 0.58(95%CI 0.42-0.80);需要呼吸机支持校正HR 0.57(95%CI 0.40-0.81);需要氧疗校正HR 0.56(95%CI 0.38-0.81)。
  • 结果在各亚组和敏感性分析中一致。

证据类型、等级与局限

  • 证据类型:基于法国国家健康数据系统的人群队列研究。
  • 局限:作者指出这些结果反映法国本土首次使用这两种免疫策略的RSV流行季,其使用应在未来研究中重新评估。

对床旁实践的改变

  • 作者认为,与母亲接种RSVpreF疫苗相比,婴儿尼塞韦单抗被动免疫与更低的RSV相关住院和重症风险相关。
  • 作者指出这些发现反映法国本土首次使用这两种免疫策略的RSV流行季,其使用应在未来研究中重新评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants. The comparative effectiveness of 2 recently introduced preventive strategies (infant immunization through placental antibody transfer after maternal vaccination with the RSV prefusion F protein [RSVpreF] vaccine and passive infant immunization with nirsevimab) remains unknown.

OBJECTIVE: To compare the associations of maternal vaccination with the RSVpreF vaccine vs passive infant immunization with nirsevimab for the prevention of RSV-related hospitalization.

DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used data from the French National Health Data System. Maternal vaccination with the RSVpreF vaccine occurred during 32 to 36 weeks' gestation among infants born in mainland France between September 1 and December 31, 2024. Passive infant immunization with nirsevimab occurred prior to hospital discharge. Infants were matched 1:1 by maternity ward discharge date, sex, gestational age, and region. Follow-up ended at the time of RSV hospitalization or death or on February 28, 2025.

EXPOSURES: Maternal immunization with the RSVpreF vaccine and passive infant immunization with nirsevimab.

MAIN OUTCOMES AND MEASURES: The primary outcome was hospitalization for RSV-associated lower respiratory tract infection. The secondary outcomes included admission to the pediatric intensive care unit (PICU), admission to high-dependency unit, ventilator support, and oxygen therapy. The hazard ratios (HRs) were estimated using conditional Cox proportional hazards models with inverse probability of treatment weighting.

RESULTS: A total of 42 560 infants (mean age, 3.7 [SD, 1.4] days; 51.7% male) were included in the study (21 280 per group) with a median follow-up of 84 days (IQR, 70-99 days). Of the 481 hospitalizations for RSV-associated lower respiratory tract infection, 212 (44.1%) occurred in the nirsevimab group vs 269 (55.9%) in the RSVpreF vaccine group (between-group difference, -11.8% [95% CI, -18.1% to -5.5%]). Compared with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with a lower risk of hospitalization for RSV-associated lower respiratory tract infection (adjusted HR, 0.74 [95% CI, 0.61 to 0.88]). Compared with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with a lower risk of severe outcomes, including PICU admission (adjusted HR, 0.58 [95% CI, 0.42 to 0.80]), requiring ventilator support (adjusted HR, 0.57 [95% CI, 0.40 to 0.81]), or requiring oxygen therapy (adjusted HR, 0.56 [95% CI, 0.38 to 0.81]). The results were consistent across subgroups and in the sensitivity analyses.

CONCLUSIONS AND RELEVANCE: Compared with maternal vaccination with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with lower risks of RSV-related hospitalization and severe outcomes. These findings reflect the first RSV season with use of these immunization strategies in mainland France; their use should be reevaluated in future studies.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Jabagi MJ, Bertrand M, Gabet A, et al. Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns. JAMA. 2026. PMID: 41428474. doi:10.1001/jama.2025.24082

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。